When will the patents on ZOLGENSMA expire, and when will biosimilar ZOLGENSMA launch?

Last updated: September 8, 2026

ZOLGENSMA, Novartis’ onasemnogene abeparvovec gene-replacement therapy, remains the highest-priced widely marketed medicine in the United States, with a list price of $2.125 million for a one-time treatment. Its commercial trajectory has been shaped by a small eligible population, durable clinical benefit, reimbursement complexity, competition from chronic therapies, and the absence of near-term biosimilar substitution. Global sales rose from $361 million in 2019 to approximately $1.37 billion in 2022 before declining to about $1.21 billion in 2023 as the launch matured and competitive pressure increased [1].

What is ZOLGENSMA and which patients can receive it?

ZOLGENSMA delivers a functional copy of the human SMN1 gene using an adeno-associated virus serotype 9, or AAV9, vector. The therapy is approved for pediatric patients younger than two years with bi-allelic mutations in the SMN1 gene, including patients who have a clinical diagnosis of spinal muscular atrophy, or SMA, and presymptomatic patients [2].

What disease does ZOLGENSMA treat?

SMA is a genetic neuromuscular disease caused by inadequate survival motor neuron protein. Severe forms can cause progressive muscle weakness, respiratory failure, and death in early childhood.

ZOLGENSMA competes with:

SPINRAZA, or nusinersen, marketed by Biogen.
EVRYSDI, or risdiplam, marketed by Roche.
Investigational and next-generation gene therapies targeting older children, adolescents, or adults.

The principal commercial distinction is treatment duration. ZOLGENSMA is administered once, while SPINRAZA requires repeated intrathecal dosing and EVRYSDI requires daily oral administration.

How much does ZOLGENSMA cost?

The U.S. wholesale acquisition cost is $2.125 million for the one-time infusion, excluding administration and related medical costs [3]. Novartis has positioned the price against the expected lifetime cost of untreated or chronically managed SMA rather than against the annual price of competing medicines.

How do payers manage the ZOLGENSMA price?

Novartis has used several reimbursement mechanisms:

Installment payment structures.
Outcomes-based agreements.
Coverage through commercial insurance and Medicaid.
Risk-sharing arrangements tied to survival or motor-function outcomes.
Reinsurance and specialty-pharmacy coordination.

The high upfront price creates a cash-flow problem for payers even when the long-term economic case is favorable. Treatment usually occurs early in life, and the economic value depends on maintaining motor milestones, reducing intensive care, and avoiding chronic supportive care.

The payment model also affects Novartis revenue recognition. Contract terms may delay or spread reported revenue compared with the date of administration. This creates a difference between treatment volume, billed price, and recognized net sales.

What are ZOLGENSMA’s sales and financial trajectory?

ZOLGENSMA generated rapid sales growth after U.S. approval, followed by a plateau as the initial launch population was treated and the market shifted toward newborn screening and competition with chronic therapies.

Fiscal year	Approximate global net sales	Commercial interpretation
2019	$361 million	Partial-year launch after May approval
2020	$920 million	Rapid U.S. and international expansion
2021	$1.01 billion	Continued geographic rollout and payer adoption
2022	$1.37 billion	Peak reported sales period
2023	$1.21 billion	Decline from peak as market matured
2024	Current figures depend on Novartis reporting period	Mature, high-value franchise with volume and pricing pressure

Sources: Novartis annual reports and financial results [1].

Why did ZOLGENSMA sales decline after 2022?

The decline reflects several factors:

The eligible prevalent population is limited because SMA is rare.
Earlier diagnosis shifts patients toward treatment before symptom progression, but does not create a large new population.
EVRYSDI and SPINRAZA retain access among patients outside the ZOLGENSMA age or clinical criteria.
Some payers require restrictive utilization management for a $2 million therapy.
International reimbursement decisions delay conversion of regulatory approval into revenue.
Gene-therapy manufacturing and administration capacity can constrain treatment timing.

ZOLGENSMA remains commercially important, but its growth profile is different from that of a conventional chronic medicine. Revenue depends more on treatment volume, geographic access, and reimbursement conversion than on price increases or expanding prescriptions.

How material is ZOLGENSMA to Novartis revenue?

Novartis reported group sales of approximately $45.4 billion in 2023. ZOLGENSMA sales of about $1.21 billion represented roughly 2.7% of group revenue [1]. The product is strategically important because it validates Novartis’ gene-therapy platform and provides a high-value specialty franchise, but it is not a major driver of consolidated company earnings relative to oncology, immunology, and cardiovascular medicines.

When does ZOLGENSMA lose regulatory exclusivity?

ZOLGENSMA received FDA approval on May 24, 2019. A licensed biological product generally receives 12 years of reference-product exclusivity in the United States under the Biologics Price Competition and Innovation Act. On that basis, U.S. biosimilar applications referencing ZOLGENSMA cannot be approved before May 24, 2031, subject to statutory rules and any applicable pediatric exclusivity [2, 4].

What is the FDA regulatory status of ZOLGENSMA?

Regulatory item	Status
Active ingredient	Onasemnogene abeparvovec-xioi
FDA approval date	May 24, 2019
Product type	AAV9 gene-replacement therapy
Administration	One-time intravenous infusion
U.S. indication	Pediatric SMA patients younger than two years with bi-allelic SMN1 mutations
Reference-product exclusivity	Generally through May 24, 2031
Biosimilar pathway	Potentially available under the BPCIA after exclusivity
Orange Book listing	Not applicable in the conventional small-molecule sense

ZOLGENSMA is a biologic, so its core regulatory reference is the Purple Book and the BPCIA rather than the Hatch-Waxman Orange Book patent-listing system [4, 5]. The absence of a conventional Orange Book listing does not eliminate patent risk. Patent disputes can still affect biosimilar development, manufacturing, and commercial launch.

What patents protect ZOLGENSMA?

ZOLGENSMA is protected by a layered estate covering the AAV vector, the SMN1 transgene, vector production, manufacturing processes, formulations, dosing, and treatment of SMA.

The most commercially relevant categories are:

Patent category	Commercial relevance
AAV9 vector technology	Protects the delivery vehicle used to transport the SMN1 gene
Recombinant AAV constructs	Covers vector design and genetic organization
SMN1 expression cassettes	Protects the therapeutic transgene and regulatory elements
Manufacturing methods	Can restrict production of clinical-grade vector at scale
Purification and analytical methods	Raises development and comparability barriers
Treatment methods	May cover patient selection, dosing, and administration
Formulation and stability	Protects storage, concentration, and product handling

Patent duration varies by patent, jurisdiction, prosecution history, terminal disclaimers, patent-term adjustment, and any regulatory extension. The practical protection period can extend into the 2030s even though the principal U.S. biologic exclusivity period ends in 2031.

How strong is the ZOLGENSMA patent estate?

The estate is technically strong because a competitor must reproduce or design around several integrated elements:

The AAV9 capsid or a functionally equivalent delivery system.
The SMN1 expression cassette.
A manufacturable vector with acceptable potency and impurity controls.
A process that can produce consistent clinical-grade material.
A formulation stable enough for distribution and administration.
Clinical and regulatory evidence supporting comparable efficacy and safety.

The estate is less absolute than a small-molecule composition-of-matter patent. A competitor could use another capsid, another expression construct, or a different manufacturing process. That strategy would require extensive nonclinical, comparability, and clinical work.

What patent litigation affects ZOLGENSMA?

ZOLGENSMA has faced AAV technology disputes involving third-party rights. REGENXBIO and other AAV technology holders have pursued claims involving vector platforms and licensed intellectual property used across the gene-therapy industry. These disputes can create damages exposure, royalty obligations, injunction risk, or licensing costs even when they do not remove ZOLGENSMA from the market.

The commercial effect of AAV litigation is usually greater on manufacturing economics and future product development than on current patient access. A court finding affecting a specific vector patent may lead to a license or damages payment rather than immediate withdrawal of an approved therapy.

Are there Paragraph IV challenges to ZOLGENSMA?

A conventional Paragraph IV challenge is unlikely to be the primary U.S. pathway for ZOLGENSMA because it is a biologic rather than a small-molecule drug approved under the Federal Food, Drug, and Cosmetic Act. Biosimilar sponsors would generally use the BPCIA patent-exchange and litigation framework, often called the patent dance, rather than file an abbreviated new drug application with a Paragraph IV certification [4].

No commercially significant U.S. biosimilar launch has displaced ZOLGENSMA. The first credible challenge is more likely to involve:

A biosimilar or interchangeable biologic application.
A patent-disclosure and negotiation process under the BPCIA.
Litigation over vector, manufacturing, formulation, or use patents.
A launch decision after the 12-year reference-product exclusivity period.

When could a ZOLGENSMA biosimilar or competing gene therapy launch?

The earliest statutory U.S. approval date for a biosimilar referencing the 2019 product is generally May 24, 2031. Commercial entry could occur later if patents remain enforceable or if the sponsor needs additional clinical and manufacturing validation.

A competing gene therapy that is not a biosimilar could enter earlier if it has a different construct, capsid, dosing strategy, or indication. Such a product would need its own biologics license application and would not automatically rely on ZOLGENSMA’s clinical package.

What generic entry risks exist?

Near-term conventional generic entry risk is negligible. The more relevant risks are:

Competing chronic therapies, especially EVRYSDI.
Off-label or expanded use of alternative SMA treatments.
New gene therapies for older or heavier patients.
Patent disputes involving AAV9 or manufacturing technology.
Payer restrictions that reduce approved-patient conversion.
Price concessions in international markets.

The risk profile changes after 2031. At that point, biosimilar development becomes legally possible, but technical barriers remain high. A biosimilar sponsor must demonstrate analytical similarity, comparable biological activity, and sufficient clinical support. AAV products also create manufacturing and assay-comparability challenges that are more complex than those for many recombinant proteins.

How does ZOLGENSMA compare with SPINRAZA and EVRYSDI?

Attribute	ZOLGENSMA	SPINRAZA	EVRYSDI
Company	Novartis	Biogen	Roche
Active therapy	Onasemnogene abeparvovec	Nusinersen	Risdiplam
Modality	AAV9 gene replacement	Antisense oligonucleotide	Oral small molecule
Administration	One-time IV infusion	Repeated intrathecal injections	Daily oral dosing
U.S. launch	2019	2016	2020
Primary commercial advantage	One-time treatment and early intervention	Broad treatment experience and long-term use	Oral convenience and broader age access
Main limitation	High upfront cost and age restriction	Repeated procedures	Chronic dosing and ongoing cost
Substitution risk to ZOLGENSMA	Moderate	Moderate	High in eligible and older patients

EVRYSDI is the most direct commercial pressure because it is oral, easier to administer, and approved across a broader age range. ZOLGENSMA retains an advantage in early pediatric treatment where a one-time intervention can preserve motor function before irreversible disease progression.

What geographic markets drive ZOLGENSMA growth?

The United States remains the largest revenue market because of high pricing and established newborn screening. Europe, Japan, and other developed markets contribute through national reimbursement decisions and managed-access programs.

Geographic expansion is limited by:

National health technology assessment requirements.
Budget-impact concerns.
Local payment structures for one-time therapies.
Treatment-center availability.
Genetic testing and newborn-screening coverage.
Differences in age eligibility and clinical guidelines.

A therapy may receive regulatory approval in a market yet produce limited revenue until national payers agree on price, outcomes measurement, and budget treatment.

What manufacturing and intellectual-property barriers protect ZOLGENSMA?

Manufacturing is a major entry barrier. A competitor must produce a high-titer AAV product with consistent potency, acceptable empty-to-full capsid ratios, low impurities, and reliable release testing.

The hardest barriers include:

Cell-culture scale-up.
Vector purification.
Removal of process impurities.
Potency assays.
Stability and cold-chain control.
Batch consistency.
Comparability after process changes.
Freedom to operate across capsid and production patents.

These barriers do not create permanent exclusivity, but they can delay entry after regulatory exclusivity ends and increase the cost of a biosimilar program.

What licensing deals support ZOLGENSMA?

Novartis acquired AveXis for approximately $8.7 billion in 2018, obtaining the ZOLGENSMA program and AveXis’ gene-therapy platform [6]. The program also relied on research and intellectual-property relationships involving AAV technology and SMA research institutions, including Nationwide Children’s Hospital.

The acquisition price reflected the expected value of a potentially curative therapy, not only the near-term revenue contribution. The return on that investment depends on maintaining premium pricing, expanding global access, and preserving manufacturing control.

Key Takeaways

ZOLGENSMA is a one-time AAV9 gene-replacement therapy for young children with SMA.
U.S. list price is $2.125 million.
Global sales rose to approximately $1.37 billion in 2022 and declined to about $1.21 billion in 2023.
The franchise is mature, with growth constrained by the small eligible population and competition from EVRYSDI and SPINRAZA.
U.S. biologic exclusivity generally extends through May 24, 2031.
Conventional Paragraph IV litigation is not the principal entry pathway because ZOLGENSMA is a biologic.
Biosimilar entry after 2031 will face substantial vector, manufacturing, analytical, and patent barriers.
The estate’s strongest protection comes from the combination of biologic exclusivity, vector patents, manufacturing know-how, regulatory complexity, and high development costs.
ZOLGENSMA represents a small portion of Novartis group revenue but remains strategically important to its gene-therapy platform.
The largest current commercial threat is chronic-treatment competition, especially oral EVRYSDI, rather than generic substitution.

FAQs about ZOLGENSMA market and patent risk

Is ZOLGENSMA still the most expensive drug in the United States?

Yes. Its U.S. wholesale acquisition cost is $2.125 million for the one-time treatment, although payer discounts and outcomes-based agreements reduce the effective net price.

Does ZOLGENSMA have an Orange Book listing?

No conventional Orange Book listing applies because ZOLGENSMA is a biologic. Its regulatory exclusivity and biosimilar framework are governed primarily by the BPCIA and FDA Purple Book system.

Can adults receive ZOLGENSMA?

The U.S. label is limited to pediatric patients younger than two years. Adults and older children generally receive alternative SMA therapies or participate in clinical studies.

Will EVRYSDI reduce ZOLGENSMA revenue?

Yes, EVRYSDI creates ongoing substitution pressure because it is orally administered and available to a broader age range. Its impact is greatest among patients who do not meet ZOLGENSMA’s age or clinical criteria.

Is ZOLGENSMA vulnerable to a biosimilar before 2031?

A U.S. biosimilar cannot generally be approved before the 12-year reference-product exclusivity period ends in May 2031. Patent disputes and technical development requirements could delay commercial entry beyond that date.

References

Novartis AG. (2024). Annual report 2023. Basel, Switzerland: Novartis.
U.S. Food and Drug Administration. (2019). FDA approves innovative gene therapy to treat pediatric patients with spinal muscular atrophy, a rare disease and leading genetic cause of infant mortality. Silver Spring, MD: FDA.
Novartis Pharmaceuticals Corporation. (2019). ZOLGENSMA prescribing information. East Hanover, NJ: Novartis.
U.S. Food and Drug Administration. (2023). Purple Book: Database of licensed biological products. Silver Spring, MD: FDA.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. Silver Spring, MD: FDA.
Novartis AG. (2018). Novartis to acquire AveXis, a leader in gene therapy, for $8.7 billion. Basel, Switzerland: Novartis.

ZOLGENSMA Drug Profile

Summary for Tradename: ZOLGENSMA

Note on Biologic Patents

1) High Certainty: US Patents for ZOLGENSMA Derived from Brand-Side Litigation

2) High Certainty: US Patents for ZOLGENSMA Derived from DrugPatentWatch Analysis and Company Disclosures

3) Low Certainty: US Patents for ZOLGENSMA Derived from Patent Text Search

ZOLGENSMA Market Dynamics, Financial Trajectory, Patent Protection, and Generic Entry Risk